• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    135.43 -0.41 (-0.31%)
    Streaming Delayed Price Updated: 2:59 PM EDT, Aug 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Merck & Co

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    News headline image
    U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Announces Fourth-Quarter 2026 Dividend
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
    From Merck & Co., Inc.
    Via Business Wire
    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
    Via Investor Brand Network
    The Quest to Repair What Multiple Sclerosis Takes Away
    Via Investor Brand Network
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
    Via Investor Brand Network
    BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    The Quest to Repair What Multiple Sclerosis Takes Away
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
    From BioMedWire
    Via GlobeNewswire
    News headline image
    U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck Animal Health to Acquire TARGAN
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
    Via ACCESS Newswire
    News headline image
    FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck to Participate in the Jefferies Global Healthcare Conference
    From Merck & Co., Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.